| 15.19 Delayed Data As of Aug 16 |  +0.28 / +1.88%Today’s Change | 11.83 Today|||52-Week Range 33.44 | -41.87% Year-to-Date |
| Why Vanda (VNDA) Might be Well Poised for a Surge Aug 08 / Zacks.com - Paid Partner Content | Vanda Pharmaceuticals Returns to Profitability in Q2 Aug 05 / MotleyFool.com - Paid Partner Content |
| Previous close | 14.91 |
| Today’s open | 15.06 |
| Day’s range | 14.81 - 15.30 |
| Volume | 724,320 |
| Average volume (3 months) | 756,453 |
| Market cap | $809.2M |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -47.11% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | +16.98% |
| P/E ratio | 28.7 |
| Price/Sales | 7.18 |
| Price/Book | 2.89 |
| Today’s change | Today’s % change | |
|---|---|---|
| KURAKura Oncology Inc | +0.40 | +2.29% |
| ALDRAlder Biopharmaceuti... | +0.34 | +3.68% |
| EGRXEagle Pharmaceutical... | +1.60 | +2.83% |
| CYTKCytokinetics Inc | +0.77 | +6.16% |
| Next reporting date | November 4, 2019 |
| EPS forecast (this quarter) | $0.07 |
| Annual revenue (last year) | $193.1M |
| Annual profit (last year) | $25.2M |
| Net profit margin | 13.05% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mihael Hristos Polymeropoulos |
Chief Financial Officer, Treasurer & Executive VP James Patrick Kelly |
Corporate headquarters Washington, District Of Columbia |
